-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Recently, Innovent announced that it will cooperate with Sanofi to accelerate the product development and market access of innovative oncology drugs, benefiting more Chinese patien.
Among them, the two parties will mainly focus on accelerating the development and commercialization of two clinical-stage core potential First-in-Class tumor pipelin.
Specifically, these two products are SAR408701 (Tusamitamab Ravtansine; anti-CEACAM5 antibody-drug conjugate) and SAR444245 (non-alpha-biased IL-
Currently, SAR408701 (tusamitamab ravtansine) is conducting Phase III clinical studies in second-line non-small cell lung cancer worldwide, as well as global Phase II clinical studies in first-line non-small cell lung cancer, gastric cancer and other solid tumo.
SAR444245 (IL-2) is conducting a global phase II clinical study in skin cancer, gastrointestinal cancer, non-small cell lung cancer/mesothelioma, head and neck cancer and lympho.
Innovent will be responsible for the clinical development and exclusive commercialization of tusamitamab in multiple tumor indications in China, and jointly explore the development of SAR444245 in multiple cancer types in China with Sano.
In addition, the two parties will also explore a series of clinical studies in combination with the PD-1 inhibitor Daboshu (sintilimab injectio.
For this cooperation, Innovent believes that it will bring long-term benefits and higher R&D capital benefits to the compa.
According to the data, Innovent Bio has currently established an innovative product pipeline with 32 new drug varieties covering major therapeutic areas such as cancer, metabolism, and autoimmune diseases, including 7 products approved in China and 3 varieties under the National Drug Administrati.
In the review of the Administration, 3 varieties are in clinical phase III or pivotal clinical research, and 19 candidate products are in pre-clinical development
In addition to Innovent Bio, Kelun Pharmaceutical also stated recently that its holding subsidiary Kelun Botai will exclusively license its biological macromolecular tumor project A (SKB264) with independent intellectual property rights to MSD in May 2022 for a fee outside of China (China includes mainland China, Hong Kong, Macau and Taiwan) regional scope research, development, manufacturing and commercializati.
In fact, in order to enhance the expansion of the research and development pipeline and accelerate the commercialization of products, it has become more and more common in the industry to join forces between pharmaceutical compani.
According to incomplete statistics, a total of 22 pharmaceutical BD transactions occurred in China in July, including 8 cross-border asset purchases, 3 cross-border asset sales, and 11 domestic transactions in Chi.
Analysts believe that strong alliances among pharmaceutical companies have become the norm, mainly due to the impact of changes in the pharmaceutical indust.
In recent years, in order to better promote the high-quality development of the pharmaceutical industry, the state has issued a series of medical reform polici.
Under the pressure of a series of policies, the elimination process of the pharmaceutical market is continuing to accelera.
In particular, with the continuous deepening of the volume-based procurement policy, a large number of generic drugs are accelerating their withdrawal from the market, while the innovative drug market has begun to develop rapid.
However, because innovation has the characteristics of large investment, high risk, and many variables, not all pharmaceutical companies can innovate independently and complete multiple innovatio.
Therefore, win-win cooperation is more and more favored by compani.
The industry expects that in the future, in order to meet more and more market challenges, accelerate the research and development of new drugs, develop combination therapies, and enhance competitiveness, a large number of domestic and foreign pharmaceutical companies will continue to join forces to achieve complementary advantages, better promote research and development innovation, accelerate Product commercializati.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyo.
Among them, the two parties will mainly focus on accelerating the development and commercialization of two clinical-stage core potential First-in-Class tumor pipelin.
Specifically, these two products are SAR408701 (Tusamitamab Ravtansine; anti-CEACAM5 antibody-drug conjugate) and SAR444245 (non-alpha-biased IL-
Currently, SAR408701 (tusamitamab ravtansine) is conducting Phase III clinical studies in second-line non-small cell lung cancer worldwide, as well as global Phase II clinical studies in first-line non-small cell lung cancer, gastric cancer and other solid tumo.
SAR444245 (IL-2) is conducting a global phase II clinical study in skin cancer, gastrointestinal cancer, non-small cell lung cancer/mesothelioma, head and neck cancer and lympho.
Innovent will be responsible for the clinical development and exclusive commercialization of tusamitamab in multiple tumor indications in China, and jointly explore the development of SAR444245 in multiple cancer types in China with Sano.
In addition, the two parties will also explore a series of clinical studies in combination with the PD-1 inhibitor Daboshu (sintilimab injectio.
For this cooperation, Innovent believes that it will bring long-term benefits and higher R&D capital benefits to the compa.
According to the data, Innovent Bio has currently established an innovative product pipeline with 32 new drug varieties covering major therapeutic areas such as cancer, metabolism, and autoimmune diseases, including 7 products approved in China and 3 varieties under the National Drug Administrati.
In the review of the Administration, 3 varieties are in clinical phase III or pivotal clinical research, and 19 candidate products are in pre-clinical development
In addition to Innovent Bio, Kelun Pharmaceutical also stated recently that its holding subsidiary Kelun Botai will exclusively license its biological macromolecular tumor project A (SKB264) with independent intellectual property rights to MSD in May 2022 for a fee outside of China (China includes mainland China, Hong Kong, Macau and Taiwan) regional scope research, development, manufacturing and commercializati.
In fact, in order to enhance the expansion of the research and development pipeline and accelerate the commercialization of products, it has become more and more common in the industry to join forces between pharmaceutical compani.
According to incomplete statistics, a total of 22 pharmaceutical BD transactions occurred in China in July, including 8 cross-border asset purchases, 3 cross-border asset sales, and 11 domestic transactions in Chi.
Analysts believe that strong alliances among pharmaceutical companies have become the norm, mainly due to the impact of changes in the pharmaceutical indust.
In recent years, in order to better promote the high-quality development of the pharmaceutical industry, the state has issued a series of medical reform polici.
Under the pressure of a series of policies, the elimination process of the pharmaceutical market is continuing to accelera.
In particular, with the continuous deepening of the volume-based procurement policy, a large number of generic drugs are accelerating their withdrawal from the market, while the innovative drug market has begun to develop rapid.
However, because innovation has the characteristics of large investment, high risk, and many variables, not all pharmaceutical companies can innovate independently and complete multiple innovatio.
Therefore, win-win cooperation is more and more favored by compani.
The industry expects that in the future, in order to meet more and more market challenges, accelerate the research and development of new drugs, develop combination therapies, and enhance competitiveness, a large number of domestic and foreign pharmaceutical companies will continue to join forces to achieve complementary advantages, better promote research and development innovation, accelerate Product commercializati.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyo.
